LOCAL APPLICATION OF GROWTH HORMONE INDUCES INCREASED IMMUNOEXPRESSION OF IGF-I ON CRANIOFACIAL BONE DEFECTS REPAIR – A PILOT STUDY

2021 ◽  
pp. 31-35
Author(s):  
Felipe Rychuv Santos ◽  
Carmen L. Mueller Storrer ◽  
Suyany Gabriely Weiss ◽  
Leandro Kluppel ◽  
João César Zielak ◽  
...  
Keyword(s):  
Growth Hormone ◽  
Bone Repair ◽  
Healing Process ◽  
Bone Defects ◽  
Local Effect ◽  
Control Group ◽  
Craniofacial Bone ◽  
Factor I ◽  
Collagen Group ◽  
Igf I

The aim is to evaluate the local effect of different concentrations of growth hormone (GH) on the repair of craniofacial bone defects, through histological, histomorfometric, and insulin-like growth factor I (IGF-I) immunoexpression assessments. Critical defects (5 mm) were performed in 32 Wistar rats. The animals were divided into four groups: Group C (Control); Group S (Sponge-collagen); Group GH 0.08 mL; GH 0.104 mg; Group GH 0.1mL. Local applications were performed 3 times a week until the rats were euthanized at 60 days. The data were submitted to ANOVA and Tukey's test (P < 0.05). A healing process with predominance of collagen bers and bone neoformation near the edges of the defect was observed in groups C and S. Islands of bone neoformation were observed at the center and edges of the defect in groups GH 0.08 and GH 0.1. In GH 0.1, the bone was more compact, and the defect was completely closed in some specimens. Bone neoformation was signicantly higher in the GH-treated groups. All the specimens stained positive for IGF-I, and this immunoexpression was signicantly higher in Group GH 0.1. In conclusion, locally applied GH signicantly favored bone repair in rat calvaria, and a higher dose of GH increased the immunoexpression of IGF-I.

Systemic metabolic effects of combined insulin-like growth factor–I and growth hormone therapy in patients who have sustained acute traumatic brain injury

2006 ◽  
Vol 105 (6) ◽  
pp. 843-852 ◽  
Author(s):  
Jimmi Hatton ◽  
Richard Kryscio ◽  
Melody Ryan ◽  
Linda Ott ◽  
Byron Young
Keyword(s):  
Growth Hormone ◽  
Growth Factor ◽  
Treatment Group ◽  
Control Group ◽  
Insulin Like Growth Factor ◽  
Gh Therapy ◽  
Factor I ◽  
Igf I ◽  
The Mean ◽  
Growth Factor I

Object Hypermetabolism, hypercatabolism, refractory nitrogen wasting, hyperglycemia, and immunosuppression accompany traumatic brain injury (TBI). Pituitary dysfunction occurs, affecting growth hormone (GH) and plasma insulin-like growth factor–I (IGF-I) concentrations. The authors evaluated whether combination IGF-I/GH therapy improved metabolic and nutritional parameters after moderate to severe TBI. Methods The authors conducted a prospective, randomized, double-blind study comparing combination IGF-I/GH therapy and a placebo treatment. Ninety-seven patients with TBI were enrolled in the study within 72 hours of injury and were assigned to receive either combination IGF-I/GH therapy or placebo. All patients received concomitant nutritional support. Insulin-like growth factor–I was administered by continuous intravenous infusion (0.01 mg/kg/hr), and GH (0.05 mg/kg/day) was administered subcutaneously. Placebo control group patients received normal saline solution in place of both agents. Nutritional and metabolic monitoring continued throughout the 14-day treatment period. The two groups did not differ in energy expenditure, nutrient intake, or use of insulin treatment. The mean daily serum glucose concentration was higher in the treatment group (123 ± 24 mg/dl) than in the control group (104 ± 11 mg/dl) (p < 0.03). A positive nitrogen balance was achieved within the first 24 hours in the treatment group and remained positive in that group throughout the treatment period (p < 0.05). This pattern was not observed in the control group. Plasma IGF-I concentrations were above 350 ng/ml in the treatment group throughout the study period. Overall, the mean plasma IGF-I concentrations were 1003 ± 480.6 ng/ml in the treatment group and 192 ± 46.2 ng/ml in the control group (p < 0.01). Conclusions The combination of IGF-I and GH produced sustained improvement in metabolic and nutritional endpoints after moderate to severe acute TBI.

The effect of growth hormone (GH) and insulin-like growth factor-I (IGF-I) on in vitro maturation of equine oocytes

Zygote ◽  
2011 ◽  
Vol 20 (4) ◽  
pp. 353-360 ◽  
Author(s):  
Gabriel Ribas Pereira ◽  
Pedro Luis Lorenzo ◽  
Gustavo Ferrer Carneiro ◽  
Barry Allen Ball ◽  
Paulo Bayard Dias Gonçalves ◽  
...  
Keyword(s):  
Growth Hormone ◽  
Growth Factor ◽  
Control Group ◽  
Factor I ◽  
Stage Of Development ◽  
Igf I ◽  
Group 15 ◽  
Cytoplasmic Maturation ◽  
Growth Factor I

SummaryThe objective of this study was to test the hypothesis that equine growth hormone (eGH), in combination with insulin growth factor-I (IGF-I), influences positively in vitro nuclear and cytoplasmic maturation of equine oocytes. Cumulus–oocyte complexes were recovered from follicles that were < 25 mm in diameter, characterized by morphology and were allocated randomly as follow: (a) control (no additives); (b) 400 ng/ml eGH; (c) 200 ng/ml IGF-I; (d) eGH + IGF-I; and (e) eGH + IGF-I + 400 ng/ml anti-IGF-I antibody. Oocytes were matured for 30 h at 38.5°C in air with 5% CO2 and then stained with 10 μg/ml propidium iodide (PI) to evaluate nuclear status and 10 μg/ml Lens culinaris agglutinin-fluorescein complex (FITC-LCA) to assess cortical granule migration by confocal microscopy. The proportion of immature oocytes that developed to the metaphase II (MII) stage in the eGH + IGF-I group (15 of 45) was greater than in the groups that were treated only with IGF-I (7 of 36, p = 0.03). Oocytes that reached MII in the control group (20 of 56; 35.7%) showed a tendency to be different when compared with eGH + IGF-I group (15 of 45; 33.3%, p = 0.08). The treated group that contained anti-IGF-I (15 of 33; 45.4%) decreased the number of oocytes reaching any stage of development when compared with eGH (47 of 72; 65.3%) and eGH + IGF-I (33 of 45; 73.3%) groups (p = 0.05) when data from MI and MII were combined. We concluded that the addition of eGH to in vitro maturation (IVM) medium influenced the in vitro nuclear and cytoplasmic maturation of equine oocytes. The use of GH and IGF-I in vitro may represent a potential alternative for IVM of equine oocytes.

Effects of insulin-like growth factor–I and platelet-rich plasma on sciatic nerve crush injury in a rat model

2011 ◽  
Vol 114 (2) ◽  
pp. 522-528 ◽  
Author(s):  
Erhan Emel ◽  
Selma Sönmez Ergün ◽  
Dilcan Kotan ◽  
Esra Başar Gürsoy ◽  
Yeşim Parman ◽  
...  
Keyword(s):  
Functional Recovery ◽  
Rat Model ◽  
Platelet Rich Plasma ◽  
Sensory Function ◽  
Local Administration ◽  
Control Group ◽  
Factor I ◽  
Igf I ◽  
Group 2 ◽  
Group 1

Object Local administration of insulin-like growth factor–I (IGF-I) has been shown to increase the rate of axon regeneration in crush-injured and freeze-injured rat sciatic nerves. Local administration of platelet-rich plasma (PRP) has been also shown to have a measurable effect on facial nerve regeneration after transection in a rat model. The objective of the study was to compare the effects of locally administered IGF-I and PRP on the parameters of the Sciatic Function Index (SFI), sensory function (SF), axon count, and myelin thickness/axon diameter ratio (G-ratio) in a rat model of crush-injured sciatic nerves. Methods The right sciatic nerve of Wistar albino rats (24 animals) was crushed using a Yasargil-Phynox aneurysm clip for 45 minutes. All animals were randomly divided into 3 groups: Group 1 (control group) was treated with saline, Group 2 was treated with IGF-I, and Group 3 was treated with PRP. Injections were performed using the tissue expander's injection port with a connecting tube directed at the crush-injured site. Functional recovery was assessed with improvement in the SFI. Recovery of sensory function was using the pinch test. Histopathological examination was performed 3 months after the injury. Results The SFI showed an improved functional recovery in the IGF-I–treated animals (Group 2) compared with the saline-treated animals (Group 1) 30 days after the injury. In IGF-I–treated rats, sensory function returned to the baseline level significantly faster than in saline-treated and PRP-treated rats as shown in values between SF-2 and SF-7. The G-ratios were found to be significantly higher in both experimental groups than in the control group. Conclusions This study suggests that the application of IGF-I to the crush-injured site may expedite the functional recovery of paralyzed muscle by increasing the rate of axon regeneration.

Longitudinal bone growth in vitro: effects of insulin-like growth factor I and growth hormone

1991 ◽  
Vol 124 (5) ◽  
pp. 602-607 ◽  
Author(s):  
Ben A. A. Scheven ◽  
Nicola J. Hamilton
Keyword(s):  
Growth Hormone ◽  
Growth Factor ◽  
Bone Growth ◽  
Long Bone ◽  
Long Bones ◽  
Insulin Like Growth Factor ◽  
Serum Free ◽  
Factor I ◽  
Igf I

Abstract. Longitudinal growth was studied using an in vitro model system of intact rat long bones. Metatarsal bones from 18- and 19-day-old rat fetuses, entirely (18 days) or mainly (19 days) composed of chondrocytes, showed a steady rate of growth and radiolabelled thymidine incorporation for at least 7 days in serum-free media. Addition of recombinant human insulin-like growth factor-I to the culture media resulted in a direct stimulation of the longitudinal growth. Recombinant human growth hormone was also able to stimulate bone growth, although this was generally accomplished after a time lag of more than 2 days. A monoclonal antibody to IGF-I abolished both the IGF-I and GH-stimulated growth. However, the antibody had no effect on the growth of the bone explants in control, serum-free medium. Unlike the fetal long bones, bones from 2-day-old neonatal rats were arrested in their growth after 1-2 days in vitro. The neonatal bones responded to IGF-I and GH in a similar fashion as the fetal bones. Thus in this study in vitro evidence of a direct effect of GH on long bone growth via stimulating local production of IGF by the growth plate chondrocytes is presented. Furthermore, endogenous growth factors, others than IGFs, appear to play a crucial role in the regulation of fetal long bone growth.

Regulation of porcine insulin-like growth factor I and growth hormone receptor mRNA expression by energy status

1994 ◽  
Vol 266 (5) ◽  
pp. E776-E785 ◽  
Author(s):  
P. A. Weller ◽  
M. J. Dauncey ◽  
P. C. Bates ◽  
J. M. Brameld ◽  
P. J. Buttery ◽  
...  
Keyword(s):  
Growth Hormone ◽  
Growth Factor ◽  
Growth Rates ◽  
Mrna Levels ◽  
Energy Status ◽  
Factor I ◽  
Receptor Mrna ◽  
Gh Receptor ◽  
Igf I ◽  
Class 1

Regulation of insulin-like growth factor I (IGF-I) and growth hormone (GH) receptor mRNA in liver and muscle by energy status was assessed in 2-mo-old pigs by altering thermoregulatory demand and energy intake over a 5-wk period to produce a range of plasma IGF-I concentrations from 3.5 +/- 0.7 to 28.9 +/- 6.2 nmol/l. These values were related directly to growth rates (0.06 +/- 0.02 to 0.44 +/- 0.01 kg/day) and total hepatic IGF-I mRNA levels. Increased growth rates were accompanied by an increase in hepatic class 1 and class 2 IGF-I mRNA levels and an increase in the ratio of class 2 to class 1 IGF-I mRNA in liver, suggesting a distinct role for class 2 expression in the endocrine growth response. High levels of class 1 transcripts and a virtual absence of class 2 transcripts characterized all muscle tissues examined, and there was no correlation with plasma IGF-I levels. This suggests that growth promotion in response to increased energy status is regulated via endocrine hepatic IGF-I rather than via a paracrine response. The levels of GH receptor mRNA were positively correlated with overall growth rate (P < 0.005) in liver and negatively correlated (P < 0.05) in muscle, indicating distinct tissue-specific effects of energy status.

scholarly journals Preliminary in Vivo Evaluation of Bone Healing in Critical Size Bone Defects Implanted with an Injectable Calcium Phosphate Bone Cement (Osteopaste)

2017 ◽  
Vol 16 (1) ◽  
Author(s):  
Che Nor Zarida Che Seman ◽  
Zamzuri Zakaria ◽  
Zunariah Buyong ◽  
Mohd Shukrimi Awang ◽  
Ahmad Razali Md Ralib @ Md Raghib
Keyword(s):  
Calcium Phosphate ◽  
Bone Cement ◽  
Bone Tissue ◽  
Bone Repair ◽  
Critical Size ◽  
Healing Process ◽  
Bone Defects ◽  
Calcium Phosphate Bone Cement ◽  
Rabbit Tibia

Introduction: A novel injectable calcium phosphate bone cement (osteopaste) has been developed. Its potential application in orthopaedics as a filler of bone defects has been studied. The biomaterial was composed of tetra-calcium phosphate (TTCP) and tricalcium phosphate (TCP) powder. The aim of the present study was to evaluate the healing process of osteopaste in rabbit tibia. Materials and method: The implantation procedure was carried out on thirty-nine of New Zealand white rabbits. The in vivo bone formation was investigated by either implanting the Osteopaste, Jectos or MIIG – X3 into a critical size defect (CSD) model in the proximal tibial metaphysis. CSD without treatment served as negative control. After 1 day, 6 and 12 weeks, the rabbits were euthanized, the bone were harvested and subjected for analysis. Results: Radiological images and histological sections revealed integration of implants with bone tissue with no signs of graft rejection. There was direct contact between osteopaste material and host bone. The new bone was seen bridging the defect. Conclusion: The result showed that Osteopaste could be a new promising biomaterial for bone repair and has a potential in bone tissue engineering.

Sign in / Sign up

Export Citation Format

Share Document